Summary
[IQVIA Oncology Dynamics (Mexico) is part of the IQVIA Global Oncology portfolio]
All regions of Mexico
(This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. The full portfolio is a global database comprising patient records spanning ten (10) countries:
- China
- France
- Germany
- Italy
- Japan
- Mexico
- Saudi Arabia
- South Korea
- Spain
- UK
Note: While this database is not a statistical sample of the Mexican population, there is a statistical panel designed using a universe study.)
IQVIA Oncology Dynamics (Mexico), part of the IQVIA Global Oncology portfolio, provides a perspective of 14 cancer drug treatment facilitating critical research in areas such as product adoption, dosing, market sizing and off-label use.
This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. This database is not a statistical sample of Mexican population; it is a descriptive cross-sectional database. The full portfolio is a global database comprising patient records spanning ten (10) countries: China, France, Germany, Italy, Japan, Mexico, Saudi Arabia, South Korea, Spain, and the UK. The global database has >200,000 patient histories available per year, collected from 2,400 physician. There are approximately 7,000 patients from Mexico expected annually, though the actual database size for Mexico may differ from this projection.
&Nbsp;
IQVIA Oncology Dynamics is a market research tool that has been designed to monitor various cancer treatments and therapies. It segments patients by indication, stage, and line of therapy to provide an understanding of patient pathways, prescribers, products, prescribing initiation and treatment practice patterns.
Potential uses of this database include help with:
(1) Determining patient segmentation and targeting based on actual clinical practice;
(2) Sizing the market accurately to assess brand potential;
(3) Monitoring brand performance, new product uptake and therapy adoption globally;
(4) Evaluating treatment flows from diagnosis to current therapy; and
(5) Benchmarking against competitor performance.
[Data in Mexico as well as other countries - Europe, Canada, China, Japan, Saudi Arabia and South Korea, are collected via a survey methodology in which physicians complete data collection forms for a number of patients per quarter. Based on their workload, physicians are asked to provide case histories from medical records and EMRs for the first "x cap" of patients seen within a specified reporting period (i.e., 15-20 patient cap depending on specialty and site to achieve a sample target by country). The reporting period is specific to country and specialty.]
Survey Data (other countries)
[Data in Mexico are collected via a survey methodology in which physicians complete data collection forms for a number of patients per quarter. Based on their workload, physicians are asked to provide case histories from medical records and EMRs for the first "x cap" of patients seen within a specified reporting period (i.e., 15-20 patient cap depending on specialty and site to achieve a sample target by country). The reporting period is specific to country and specialty.]
(Approximately 35 days after the end of a quarter)
(Q1 2018 - Present)
Inpatient
Survey covers all 14 cancer types and stages:
ALL;
CML;
CLL;
NHL;
Breast;
NSCLC;
Prostate;
Colorectal;
Bladder;
Kidney;
Multiple Myeloma,
Pancreas;
Ovarian; and
Melanoma.
(Cancer patients being treated in a hospital inpatient or outpatient setting)
Survey covers all 14 cancer types and stages:
ALL;
CML;
CLL;
NHL;
Breast;
NSCLC;
Prostate;
Colorectal;
Bladder;
Kidney;
Multiple Myeloma,
Pancreas;
Ovarian; and
Melanoma.
(Cancer patients being treated in a hospital inpatient or outpatient setting)
[The IQVIA Oncology Dynamics (Mexico) database is updated on an ongoing basis;
This profile was developed for the B.R.I.D.G.E. TO DATA site on April 20, 2021.]
Population Dynamics
[Not applicable, as this is a cross-sectional survey with natural fallout collection. More specifically, annual sample targets for the database are not collected by indication and instead there are selection criteria for physician case reports to remove any bias (i.e., natural fall out).
Physicians are required to report the first consecutive cases during the reporting period. There is a limit to the number of cases that any one physician can report, regardless of indication.]
The sample is not weighted in any way. It is meant to give a representative view of the treated prevalent cancer population.
(Not applicable, as this database collects data on a quarterly basis)
Demographic Data
(Collected in 5-year brackets)
Patients in the database are considered representative of the overall patient population
Patients in the database are considered representative of the overall patient population
All areas of Mexico
Patients that are reported in the database are currently actively treated, i.e., are alive when reported
(Not applicable)
Physician & Practioner Info
All physicians have a unique ID number; however, this information is not available in the database.
(Not applicable, as no pharmacy data are collected)
Diagnoses/Signs & Symptoms
Data collection covers all aspects of the patient’s chemotherapy treatment including:
- Cancer diagnosis;
- Histology;
- Assignment therapy;
- Date & time of tests;
- Surgery;
- Platinum status (sensitive or refractory);
- Date & time of therapy;
- Details of the therapy administered; and
- Full demographics that include stage of disease at diagnosis and at relapse. Regular reporting by a panel of physicians in Mexico provides stability in the data.
Drug-treated patients are reported in the database:
1. Date of diagnosis and stage at diagnosis are captured. Therapy type at diagnosis is not necessarily captured unless the patient is newly diagnosed.
2. Patient's current treatment and one historic/previous treatment are captured. The dates of each reported therapy are also captured.
3. Full patient demographics are always captured.
(Q1 2018 - Present)
Includes:
Biomarkers;
Ecog Performance Status;
Metastatic Status;
Year Of Diagnosis;
Relapse & Progression;
Co-Morbidities;
Smoking Status; and
Stem Cell Transplant.
Survey covers all 14 cancer types and stages:
ALL;
CML;
CLL;
NHL;
Breast;
NSCLC;
Prostate;
Colorectal;
Bladder;
Kidney;
Multiple Myeloma,
Pancreas;
Ovarian; and
Melanoma.
(Cancer patients being treated in a hospital inpatient or outpatient setting)
Data are often collected on smoking status; However, there is no information regarding alcohol consumption.
Procedures
This database only captures data on patients undergoing treatment. Drug treatment options include both anticancer drugs and supportive care. Information is also available on treatment practice patterns and other treatment details, including tumor type, stage. Key biomarker test results are collected.
(Q1 2018 - Present)
Key biomarker test and chromosomal abnormalities results are collected. There is information on imaging or blood count results. A list of available tests by cancer type can be provided upon request.
Data on diagnostic tests results are available, such as:
HER2 status;
KRAS status;
hormone receptor status;
PD-1/PD-L1;
EGFR plus some EGFR subtypes;
ALK BRAF;
BRCA;
CMET;
NRAS;
ROS-1;
Platinum status PSA; and
Gleason Score.
Chromosomal abnormalities in haematological cancers include:
CLL;
MM;
CML; and
AML.
Drug Information
Information is collected on anticancer drugs and some supportive care drugs. Information on biosimilars will be available as they become available on the market, e.g.:
Molecule;
Regimen;
Route of Admin;
Dose Quantity and Frequency;
Cycles Planned vs. Given;
Treatment Funding;
Maintenance Therapy;
Therapy Initiator;
Side Effects; and
Therapy Context.
(Q1 2018 - Present)
Information is collected on:
Route of administration;
Number of times administered per day; and
Number of days given per cycle.
Information is collected on:
Duration for completed drugs;
Any ongoing treatments;
Planned durations; and
Number of cycles.
However, this is limited by character length in data entry field.
NOTE: Some regimens have multiple drugs.
(Not applicable)
Generic and brand name (where applicable) is requested.
Biobanks
Genetic-PGx Data
Economic Data
(Not applicable)
(Not applicable)
(Not applicable)
Validation & Linkage
However, numerous quality checks are performed on the data collected to ensure accuracy
N/A
(Not applicable)
Administrative Data
E-Mail: RWDassets@IQVIA.com
N/A
(Not applicable)
(IQVIA)
(Not applicable)
N/A
(Not applicable)
(This is a subscription database available to the pharmaceutical industry)
Pricing depends on client interest / project scope
(Access through various analytical formats)
(Not applicable; there are no publications as this is a new database)
N/A
(Not applicable; there are no publications as this is a new database)
Database Contact
E-Mail: RWDassets@IQVIA.com
N/A
Literature References
N/A